Skip to content

Biosimilars news

Biosimilars Canada has compiled a list of news stories from Canada and abroad about biosimilars that may be of interest to readers. These links to third-party websites are provided for informational purposes only, and do represent an endorsement from our organization. Biosimilars Canada’s statements and news releases are available here.

Canadian Trends and Projections in Prescription Drug Purchases: 2001-2023

Peer-reviewed article published in the Canadian Journal of Health Technologies highlights the importance of biosimilar switching policies in curbing sustained growth in pharmaceutical spending in Canada, and avoiding a shift in spending from other public budgets or to private industry and patients. 

Read more

Study Models Biosimilar Savings in Ontario From Mandatory Switching

Report by the Center for Biosimilars on a new ODPRN study which estimates significant savings from biosimilars in Ontario based on mandatory switching programs.

Read more

Projected Impact of Biosimilar Substitution Policies on Drug Use and Costs in Ontario

New study from the Ontario Drug Policy Research Network (ODPRN) that estimates the number of patients potentially impacted by different biosimilar policy options in Ontario and the cost implications of these policies. Published in CMAJ Open.

Read more

Drug Plans Decoded: Biosimilars Part 3

The Pharmacy Consulting Team at Telus Health looks at how public drug plans are helping to drive the adoption of biosimilars in Canada. Third in series.

Read more

The case for an Ontario biosimilar switching policy

The Government of Ontario spending $3 million more than it needs to on biologic drugs every single week. Biosimilars are the solution, writes Biosimilars Canada President Jim Keon in his op-ed for QP Briefing.

Read more

Prescribed drug spending in Canada, 2021

This report from Canadian Institute for Health Information (CIHI) found that the uptake of biosimilars continued to increase in 2020, but reference biologic drugs continued to account for the majority of drug spending. When biosimilars were available for the reference biologic products, they accounted for 28.5% of biologic spending in 2020, up from 16.1% in 2019. 

Read more